La Jolla
A bit of history
Speculators Frank T. Botsford and George W. Heald began developing La Jolla as a seaside resort during the real estate boom of the 1880s, and a rail line and hotel by 1894 drew early vacationers. Philanthropist Ellen Browning Scripps arrived in 1896 and became the neighborhood's principal developer, commissioning landmark buildings and helping fund the Scripps Institution of Oceanography, founded in 1903, which later anchored the creation of UC San Diego. That research base has since grown into a cluster of institutions including the Salk Institute, Scripps Research, and the Sanford Burnham Prebys Medical Discovery Institute, making La Jolla one of the region's leading biotech and research centers.
$200.0MAnchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
Series A$99.0MEnlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.
Series B$27.1MFounded and led by Dr. Quyen Nguyen, a UC San Diego head-and-neck surgeon named to Forbes' 50 Over 50 Innovation list.
Series B$20.3MSYLKE® Skin Closure is a sterile, single-use, silk fibroin mesh strip with a pressure-sensitive adhesive intended for topical skin closure and wound support. The device is used to hold together well-approximated skin edges of a wound, and to cover and protect the wound. Learn more at sylke.com.
Seed$18.6MFounded by Dr. Stella Sarraf; its ALS drug candidate SPG302 received an FDA-authorized expanded access program in 2025.
Series B$18.5MPaulex Bio stands at the threshold of what could be a transformative breakthrough for type 1 and type 2 diabetes: beta cell regeneration through an oral medicine designed to eliminate the root cause of diabetes.
Series A$15.7MModel Medicines engineers first-in-class small molecules against biological choke points, using AI to advance pipeline-in-a-pill therapeutics across high-impact diseases.
Seed$14.8MWe explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.
Series C$13.1M
Seed$13.0MValora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.
Series C$10.5MGenerate more event revenue with Events.com. Sell tickets online, promote your events, find sponsors, and grow your event business.
Series A$10.4MAeroRx Therapeutics is developing potential best-in-class nebulized combination therapies to improve COPD treatment.
$10.0MLearn how Genomic Life enhances health and well-being through genetic screenings, early detection, personalized cancer navigation, and ongoing support. Optimize employee benefits and create a healthier workforce.
RightDevice was co-founded by George Kramb and Patrick Frank and later rebranded as PatientPartner, a platform connecting patients with medical device information and providers.
Series A$1.9MA28 Therapeutics is a clinical stage biopharmaceutical company developing a novel platform technology to treat multiple cancer types
Seed$1.0MUsing Clinical Insights to Guide Patient Traffic Flow — DEPTH™ accelerates care velocity across the patient journey through Augmented Surveillance Intelligence.
Seed$950KImpulse Medical Technologies - A leading manufacturer and distributor of high-quality medical electrodes and diagnostic supplies. Parent company of The Electrode Store and TES Wholesale.
Seed$800KViroMissile is developing the world’s first truly intravenously-delivered viruses that target and kill tumors.
Series A$762KGRI Bio is a publicly traded clinical-stage biopharmaceutical company (Nasdaq: GRI), led by CEO Marc Hertz, PhD.
$550KTIGER HOSPITALITY - Elevating San Diego
Series A$32KJoin The Mortgage Collaborative — a leading mortgage lender and preferred partner network helping mortgage professionals grow through collaboration, resources, and industry expertise.
Busa Beverage was conceptualized by the Busalacchi family, owners of the Barbusa restaurant in San Diego's Little Italy, and makes what it calls the first oat-milk bottled espresso martini.